急性早幼粒白血病细胞ATRA耐药株HL-60R、NB4R的构建及鉴定  

Establishment and identification of human acute promyelocytic leukemia ATRA-resistant cell lines HL-60R and NB4R

作　　者：张亚芬[1] 张莹[1] 缪凤琴[1] 张建琼[1] 

机构地区：[1]东南大学医学院病原生物学与免疫学系,发育与疾病相关基因教育部重点实验室,江苏南京210009

出　　处：《东南大学学报（医学版）》2014年第5期569-572,共4页Journal of Southeast University(Medical Science Edition)

基　　金：国家自然科学基金资助项目(81371609)

摘　　要：目的:构建急性早幼粒细胞白血病细胞系HL-60、NB4的全反式维甲酸耐药株HL-60R、NB4R,并对其生物学性状进行鉴定。方法:以全反式维甲酸(ATRA)为诱导药物,采用浓度递增间歇诱导法构建HL-60、NB4细胞相应的ATRA耐药株。CCK8法鉴定其ATRA耐药性,并检测耐药细胞株的生长曲线及多药耐药性。结果:成功构建了ATRA耐药细胞株HL-60R、NB4R,并发现与亲代细胞相比,其生长增殖速度减慢,群体倍增时间延长,且对其它多种化疗药物产生一定程度的交叉耐药。结论:成功构建的耐药细胞系HL-60R、NB4R为急性早幼粒细胞白血病多药耐药机制的进一步研究奠定了基础。Objective： To establish human acute promyelocytic leukemia （ APL ） ATRA-resistant cell lines and to explore their biological characteristics.Methods： Human APL ATRA-resistant cell lines HL-60 R and NB4 R were established by stepwise increasing concentrations of ATRA selection from the parental cell lines HL-60 and NB4.Drug sensitivity of resistant cells was detected by CCK8 assay,and the changes of biological characteristics were determined by light microscopy and cell counting.Results： Human APL ATRA-Resistant cell lines HL-60R and NB4R were developed with stable resistance to ATRA .Compared to parental cells, HL-60R and NB4R cells grew more slowly and had a longer doubling time .Besides,HL-60R and NB4R cells exhibited cross-resistance to etoposide , vincristine sulfate , cytarabine and doxorubicin .Conclusion：HL-60 R and NB4 R cells are reliable multi-drug resistant cell sublines of APL .The successful establishment of these cells has laid a solid foundation for further study of the multi-drug resistant mechanism of human APL induced by ATRA .

关 键 词：急性早幼粒细胞白血病 全反式维甲酸 多药耐药 HL-60R NB4R 

分 类 号：R-33[医药卫生] R733.71